StreetInsider.com News Articles

Form 424B3 CERO THERAPEUTICS HOLDIN

Fri, 17 Jul 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260717/26784901.html

Form 424B3 CERO THERAPEUTICS HOLDIN

Fri, 17 Jul 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260717/26784901.html

Form 8-K CERO THERAPEUTICS HOLDIN For: Jul 14

Fri, 17 Jul 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260717/26784791.html

Form 8-K CERO THERAPEUTICS HOLDIN For: Jul 14

Fri, 17 Jul 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260717/26784791.html

Form 25-NSE CERO THERAPEUTICS HOLDIN Filed by: Nasdaq Stock Market LLC

Mon, 13 Jul 2026 13:28:00 -0400

si-local-file:///var/storage/secattach/20260713/26761853.html

Form 25-NSE CERO THERAPEUTICS HOLDIN Filed by: Nasdaq Stock Market LLC

Mon, 13 Jul 2026 13:28:00 -0400

si-local-file:///var/storage/secattach/20260713/26761853.html

Form 424B3 CERO THERAPEUTICS HOLDIN

Fri, 26 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260626/26698779.html

Form 424B3 CERO THERAPEUTICS HOLDIN

Fri, 26 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260626/26698779.html

Form 8-K CERO THERAPEUTICS HOLDIN For: Jun 23

Fri, 26 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260626/26698711.html

Form 8-K CERO THERAPEUTICS HOLDIN For: Jun 23

Fri, 26 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260626/26698711.html

Form 424B3 CERO THERAPEUTICS HOLDIN

Fri, 29 May 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260529/26575416.html

Form 424B3 CERO THERAPEUTICS HOLDIN

Fri, 29 May 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260529/26575416.html

Form 8-K CERO THERAPEUTICS HOLDIN For: May 28

Fri, 29 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260529/26575043.html

Form 8-K CERO THERAPEUTICS HOLDIN For: May 28

Fri, 29 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260529/26575043.html

Form 424B3 CERO THERAPEUTICS HOLDIN

Fri, 15 May 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260515/26506856.html

Form 424B3 CERO THERAPEUTICS HOLDIN

Fri, 15 May 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260515/26506856.html

Form 10-Q CERO THERAPEUTICS HOLDIN For: Mar 31

Fri, 15 May 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260515/26505638.html

Form 10-Q CERO THERAPEUTICS HOLDIN For: Mar 31

Fri, 15 May 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260515/26505638.html

CERo Therapeutics completes second cohort of phase 1 cancer trial

Mon, 11 May 2026 08:15:18 -0400

CERo Therapeutics Holdings Inc. (OTCQB: CERO) completed dosing and the 28-day dose-limiting toxicity assessment period for three patients in the second cohort of its Phase 1 CERTAIN-T clinical trial of CER-1236 for blood cancers.

In the second cohort, patients received CER-1236 at a total dose of 4 × 10⁶ cells/kg, administered as a split dose on Day 0 and Day 2. The company reported no dose-limiting toxicities were observed through the assessment window, allowing for continued dose escalation according to the clinical protocol.

The company is now escalating to the planned 1 × 10⁷ cells/kg split-dose cohort and screening patients for enrollment.

CERo Therapeutics completes second cohort of phase 1 cancer trial

Mon, 11 May 2026 08:15:18 -0400

The company is now escalating to the planned 1 × 10⁷ cells/kg split-dose cohort and screening patients for enrollment.

CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

Mon, 11 May 2026 08:15:00 -0400

Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis

SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company advancing next-generation engineered T cell therapeutics that employ phagocytic mechanisms, announces that it has completed dosing and the 28-day dose-limiting toxicity (“DLT”) assessment period for all three patients in the second cohort of its Phase 1 CERTAIN-T clinical trial of CER-1236 in hematologic malignancies.

In the second cohort, patients received CER-1236 at a

CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

Mon, 11 May 2026 08:15:00 -0400

Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis

In the second cohort, patients received CER-1236 at a

CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

Mon, 11 May 2026 08:15:00 -0400

Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis

In the second cohort, patients received CER-1236 at a

CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

Mon, 11 May 2026 08:15:00 -0400

Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis

In the second cohort, patients received CER-1236 at a

Form 424B3 CERO THERAPEUTICS HOLDIN

Fri, 01 May 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260501/26417755.html